

Sebastien Lacroix-Desmazes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/299353/publications.pdf>

Version: 2024-02-01

72
papers

3,065
citations

201385

27
h-index

161609

54
g-index

74
all docs

74
docs citations

74
times ranked

3009
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutting Edge: Human CD4+CD25+ T Cells Restrain the Maturation and Antigen-Presenting Function of Dendritic Cells. <i>Journal of Immunology</i> , 2004, 172, 4676-4680.	0.4	415
2	Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. <i>Blood</i> , 2008, 111, 715-722.	0.6	252
3	IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. <i>Nature Medicine</i> , 2020, 26, 1096-1101.	15.2	193
4	Catalytic activity of antibodies against factor VIII in patients with hemophilia A. <i>Nature Medicine</i> , 1999, 5, 1044-1047.	15.2	186
5	VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. <i>Blood</i> , 2007, 109, 610-612.	0.6	179
6	High levels of catalytic antibodies correlate with favorable outcome in sepsis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4109-4113.	3.3	110
7	A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8965-8970.	3.3	110
8	The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A. <i>New England Journal of Medicine</i> , 2002, 346, 662-667.	13.9	107
9	Antibody Polyreactivity in Health and Disease: Statu Variabilis. <i>Journal of Immunology</i> , 2013, 191, 993-999.	0.4	100
10	Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 262-272.	3.2	94
11	Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. <i>Blood</i> , 2008, 112, 240-249.	0.6	80
12	Inhibitors in hemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 109-124.	0.5	75
13	Ferrous Ions and Reactive Oxygen Species Increase Antigen-binding and Anti-inflammatory Activities of Immunoglobulin G. <i>Journal of Biological Chemistry</i> , 2006, 281, 439-446.	1.6	72
14	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. <i>Blood</i> , 2014, 123, 121-125.	0.6	63
15	Tolerating Factor VIII: Recent Progress. <i>Frontiers in Immunology</i> , 2019, 10, 2991.	2.2	52
16	Catalytic IgG from Patients with Hemophilia A Inactivate Therapeutic Factor VIII. <i>Journal of Immunology</i> , 2006, 177, 1355-1363.	0.4	45
17	Factor VIII Hydrolysis Mediated by Anti-Factor VIII Autoantibodies in Acquired Hemophilia. <i>Journal of Immunology</i> , 2008, 180, 7714-7720.	0.4	45
18	Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. <i>Science Translational Medicine</i> , 2015, 7, 275ra21.	5.8	43

#	ARTICLE	IF	CITATIONS
19	Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. <i>Haematologica</i> , 2007, 92, 1423-1426.	1.7	40
20	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. <i>Blood</i> , 2011, 117, 2257-2264.	0.6	38
21	Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. <i>Haematologica</i> , 2015, 100, 149-156.	1.7	37
22	Immunogenicity of long-lasting recombinant factor VIII products. <i>Cellular Immunology</i> , 2016, 301, 40-48.	1.4	37
23	Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. <i>Haematologica</i> , 2008, 93, 83-89.	1.7	34
24	Autoantibodies with enzymatic properties in human autoimmune diseases. <i>Journal of Autoimmunity</i> , 2011, 37, 144-150.	3.0	34
25	CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells. <i>Blood Advances</i> , 2017, 1, 1842-1847.	2.5	32
26	The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. <i>Haematologica</i> , 2017, 102, 271-281.	1.7	29
27	Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. <i>Haematologica</i> , 2013, 98, 1650-1655.	1.7	29
28	Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. <i>Blood</i> , 2010, 115, 2682-2685.	0.6	28
29	Heterogeneous antigen recognition behavior of induced polyspecific antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 266-271.	1.0	27
30	A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 37, 105-113.	2.9	24
31	Antibody-mediated catalysis: Induction and therapeutic relevance. <i>Autoimmunity Reviews</i> , 2013, 12, 648-652.	2.5	24
32	Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes. <i>Diabetes</i> , 2015, 64, 3532-3542.	0.3	24
33	Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?. <i>Haematologica</i> , 2019, 104, 236-244.	1.7	23
34	Hydrolysis of Coagulation Factors by Circulating IgG Is Associated with a Reduced Risk for Chronic Allograft Nephropathy in Renal Transplanted Patients. <i>Journal of Immunology</i> , 2008, 180, 8455-8460.	0.4	22
35	A Cryptic Polyreactive Antibody Recognizes Distinct Clades of HIV-1 Glycoprotein 120 by an Identical Binding Mechanism. <i>Journal of Biological Chemistry</i> , 2014, 289, 17767-17779.	1.6	19
36	Functional variability of antibodies upon oxidative processes. <i>Autoimmunity Reviews</i> , 2008, 7, 574-578.	2.5	18

#	ARTICLE	IF	CITATIONS
37	Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins. <i>Journal of Immunology</i> , 2008, 181, 1609-1615.	0.4	18
38	Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. <i>FEBS Letters</i> , 2009, 583, 2565-2572.	1.3	18
39	Thermodynamic Analysis of the Interaction of Factor VIII with von Willebrand Factor. <i>Biochemistry</i> , 2012, 51, 4108-4116.	1.2	17
40	Complement C3 is a novel modulator of the anti-factor VIII immune response. <i>Haematologica</i> , 2018, 103, 351-360.	1.7	17
41	Noncanonical Functions of Antibodies. <i>Trends in Immunology</i> , 2020, 41, 379-393.	2.9	17
42	Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1172-1173.	1.5	16
43	Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries. <i>Journal of Immunological Methods</i> , 2014, 407, 26-34.	0.6	16
44	Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A. <i>Thrombosis and Haemostasis</i> , 2003, 90, 813-822.	1.8	15
45	The role of VWF in the immunogenicity of FVIII. <i>Thrombosis Research</i> , 2008, 122, S3-S6.	0.8	15
46	Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA. <i>Haematologica</i> , 2020, 105, 1129-1137.	1.7	15
47	A novel molecular analysis of genes encoding catalytic antibodies. <i>Molecular Immunology</i> , 2012, 50, 160-168.	1.0	13
48	“Rational Vaccine Design” for HIV Should Take into Account the Adaptive Potential of Polyreactive Antibodies. <i>PLoS Pathogens</i> , 2011, 7, e1002095.	2.1	12
49	Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. <i>PLoS ONE</i> , 2019, 14, e0218258.	1.1	12
50	Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy. <i>Haemophilia</i> , 2020, 26, 958-965.	1.0	11
51	Key insights to understand the immunogenicity of FVIII products. <i>Thrombosis and Haemostasis</i> , 2016, 116, S2-S9.	1.8	10
52	Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 517-530.	1.5	10
53	Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. <i>Frontiers in Immunology</i> , 2020, 11, 810.	2.2	10
54	Absence of a neutralizing antibody response to humanized cobra venom factor in mice. <i>Molecular Immunology</i> , 2018, 97, 1-7.	1.0	9

#	ARTICLE	IF	CITATIONS
55	Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1093-1098.	1.8	8
56	Emergence of antibodies endowed with proteolytic activity against High-mobility group box 1 protein (HMGB1) in patients surviving septic shock. <i>Cellular Immunology</i> , 2020, 347, 104020.	1.4	7
57	Human mannose receptor (CD206) in immune response: novel insights into vaccination strategies using a humanized mouse model. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 677-681.	1.3	6
58	Inhibitorsâ€”Recent insights. <i>Haemophilia</i> , 2021, 27, 28-36.	1.0	6
59	Catalytic antibodies in patients with systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , 2018, 5, 173-178.	1.3	6
60	Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 229-234.	0.5	4
61	Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. <i>Cellular Immunology</i> , 2018, 325, 64-68.	1.4	4
62	Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors. <i>Cellular Immunology</i> , 2018, 331, 22-29.	1.4	4
63	Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A. <i>Haematologica</i> , 2019, 104, 1046-1054.	1.7	4
64	Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. <i>Haematologica</i> , 2019, 104, e369-e372.	1.7	4
65	Inhibitors of Factor VIII in Hemophilia. <i>New England Journal of Medicine</i> , 2009, 361, 308-310.	13.9	3
66	Varied Immune Response to FVIII: Presence of Proteolytic Antibodies Directed to Factor VIII in Different Human Pathologies. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 37, 97-104.	2.9	3
67	Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice. <i>Immunology</i> , 2010, 131, 549-555.	2.0	3
68	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. <i>Journal of Immunology</i> , 2016, 196, 4075-4081.	0.4	3
69	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. <i>Frontiers in Immunology</i> , 2020, 11, 393.	2.2	3
70	IVIg Treatment Reduces Catalytic Antibody Titers of Renal Transplanted Patients. <i>PLoS ONE</i> , 2013, 8, e70731.	1.1	3
71	A molecular jewel for hemophilia A treatment. <i>Blood</i> , 2020, 135, 1417-1419.	0.6	2
72	Monoepitopic anti-FVIII T-cell response. <i>Blood</i> , 2016, 128, 1999-2001.	0.6	1